Tarsus Pharma appoints Jeff Farrow as CFO and Chief Strategy Officer; Leo Greenstein departs

Tarsus Pharmaceuticals, Inc.

Leo Greenstein left as CFO effective April 24, 2023; employment continues through June 15, 2023.
Jeff Farrow appointed CFO and Chief Strategy Officer effective April 24, 2023; previously CFO at Global Blood Therapeutics, ZS Pharma, and Hyperion Therapeutics.
Farrow receives $500,000 base salary, $100,000 signing bonus (paid in two tranches), and 40% annual bonus target.
Equity awards: RSUs and options each with $1.5M target value; RSUs vest 25% annually over 4 years starting June 15, 2024.
Severance: 9 months base salary (non-CIC) or 12 months base plus accelerated vesting and prorated bonus (CIC).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeff Farrow

Chief Financial Officer and Chief Strategy Officer

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2023-04-24
Filed: April 24, 2023, 7:59 PM ET

The Company also announced the appointment of Jeff Farrow as the Company’s Chief Financial Officer and Chief Strategy Officer, also effective as of the Transition Date.

Departed

Leo Greenstein

Chief Financial Officer

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2023-04-24
Successor: Jeff Farrow
Filed: April 24, 2023, 7:59 PM ET

On April 24, 2023, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Leo Greenstein would be leaving his role as the Company’s Chief Financial Officer (the “Transition”), effective as of April 24, 2023 (the “Transition Date”) and leaving his employment with the Company on June 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeff Farrow was appointed as Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer and Chief Strategy Officer

Exact text from the filing

The Company also announced the appointment of Jeff Farrow as the Company’s Chief Financial Officer and Chief Strategy Officer, also effective as of the Transition Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Leo Greenstein changed role as Chief Financial Officer at Tarsus Pharmaceuticals, Inc..

Action: leaving his role
Role: Chief Financial Officer

Exact text from the filing

On April 24, 2023, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Leo Greenstein would be leaving his role as the Company’s Chief Financial Officer (the “Transition”), effective as of April 24, 2023 (the “Transition Date”) and leaving his employment with the Company on June 15, 2023.

View on SEC.gov

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-112926

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.